BMJ Open Ophthalmology

Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy

Anil Parajuli ⁽¹⁾, ¹ Purushottam Joshi ⁽²⁾

ABSTRACT

To cite: Parajuli A, Joshi P. Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy. *BMJ Open Ophthalmology* 2020;**5**:e000540. doi:10.1136/ bmjophth-2020-000540

Received 9 June 2020 Revised 21 October 2020 Accepted 8 November 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Glaucoma, Mechi Eye Hospital, Birtamode, Nepal ²Retina, Pediatric Ophthalmolgy and Strabismus, Cataract, Mechi Eye Hospital, Birtamode, Nepal

Correspondence to Dr Anil Parajuli; anil. parajuli861@gmail.com **Objective** To investigate the factors affecting the duration of subretinal fluid (SRF) resolution and their correlation with the final anatomical and functional outcome in cases of treatment naïve acute central serous chorioretinopathy (CSCR).

Methods and analysis We retrospectively studied 93 eyes of 93 patients diagnosed with treatment naïve acute CSCR presenting within 30 days of onset of symptoms. The eyes were divided into two groups (1 and 2) based on the duration of SRF resolution; which was ≤ 3 months in group 1 and >3 months in group 2. Demographic and medical history, and spectral domain optical coherence tomography features were noted and their association with duration for SRF resolution, final central macular thickness (CMT) and final best-corrected visual acuity (BCVA) were studied. All the patients were prescribed topical non-steroidal antiinflammatory drug for 1 month at the diagnosis of CSCR. **Results** Longer duration of symptoms, female gender and baseline OCT factors like hyper-reflective dots and retinal pigment epithelial bumps were associated with longer duration for SRF resolution (p<0.001, p=0.04, p=0.001 and p=0.01, respectively). The SRF resolution time had strong correlations with the final CMT (r=-0.589) p<0.001) and final BCVA in logarithm of minimum angle of resolution (LogMAR) (r=+0.599, p<0.001). Group 2 eyes had worse final BCVA and thinner final CMT than Group 1 (both p<0.001). The final CMT of the patients of Group 1 was statistically thinner than the normal population (p<0.001).

Conclusion Patient's baseline clinicodemographic and OCT features can be used to predict the course and visual outcome in cases of treatment naïve acute idiopathic CSCR.

INTRODUCTION

Central serous chorioretinopathy (CSCR) is one of the most common chorioretinal pathologies. It is classically characterised by one or multiple neurosensory retinal detachments with the occurrence of subretinal fluid (SRF), with or without presence of a clinically detectable pigment epithelial detachment (PED).¹ CSCR usually affects middle-aged men, however, it can be seen in patients from 20 to 64 years of age.^{2 3} The mean age in

Key Messages

What is already known about this subject?

- Central serous chorioretinopathy (CSCR) is a selflimiting disease.
- Chronic CSCR is often associated with poor visual outcome.

What are the new findings?

- Female gender and the presence of hyper-reflective dots (HRDs) and retinal pigment epithelial (RPE) bumps in the baseline OCT are associated with longer duration for subretinal fluid resolution.
- Patients with HRDs have poor final visual outcome.

How might these results change the focus of research or clinical practice?

In cases of CSCR, females and patients with HRDs and RPE bumps in baseline OCT might do better with interventions other than topical non-steroidal antiinflammatory drug.

various studies is noted to range from 39 to 51 years.^{3 4} There is male preponderance and the reported male to female ratio varies from $2.7:1^5$ to $7:1.^6$

Various theories have been proposed regarding the possible cause of CSCR. However, recent investigations have suggested that choroidal vascular hyperpermeability may be the principal underlying pathology.^{7–10}

Most cases of acute CSCR resolve spontaneously within 6 months and more than 80% of the patients regain a visual acuity of better than 20/30.¹¹ However, 5% of patients may experience severe vision loss to 20/200 or even worse because of chronicity and retinal pigment epithelial (RPE) atrophy.¹²

The chronicity of the SRF has been directly linked to the final anatomical and functional outcome of the CSCR patients. The presence of chronic SRF is believed to cause photoreceptor death resulting in permanent deterioration of vision.¹³ The mechanism is believed to be the hypoxic damage to the outer retina due to its prolonged separation from the RPE and choroid. 14

Spectral domain optical coherence tomography (SD-OCT) has proven useful for the study of the cases of CSCR due to its non-invasive nature, excellent diagnostic value and its aid in treatment follow-up. Various features like PED, fibrin, RPE bumps, hyper-reflective dots (HRDs) in the intraretinal and/or subretinal layer, and disrupted ellipsoid zone are seen in the OCT in cases of CSCR, which help to predict the disease duration and the prognosis of the disease.^{15–17}

A better understanding of these factors would help in early identification and treatment of the cases at higher risk of chronicity to prevent the damage of photoreceptor and RPE. The purpose of this study was to see the effects of the various baseline clinicodemographic and OCT features on the duration of the disease and the anatomical and functional outcome in cases presenting with treatment naïve acute idiopathic CSCR.

MATERIALS AND METHODS

This retrospective, descriptive study was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. We obtained the consent for the use of data for research from all patients.

All enrolled patients were diagnosed as treatment naïve acute idiopathic CSCR at Mechi Eye Hospital, Jhapa, Nepal, between January 2017 and November 2018. The diagnosis of acute CSCR required a visible or clinically suspected serous neuroretinal detachment of any part of the macula and its documentation by OCT. None of the patients enrolled in the study underwent fundus fluorescence angiography or OCT angiography. Only those cases with history of first episode, with symptoms occurring within the preceding 30 days were included in the study. In case of bilateral involvement, only the first eye to develop the condition was included. Cases needed to have a minimum follow-up of 6 months. The patients' final BCVA and final central macular thickness (CMT) were recorded at 6 months follow-up or after 1 month of resolution of SRF, whichever was longer. Exclusion criteria included: (1) neurosensory retinal detachment secondary to diseases other than CSCR; (2) severe media opacities; (3) advanced glaucoma; (4) trauma; (5) high myopia; (6) posterior uveitis; (7) age-related macular degeneration; (8) angoid streaks and (9) those associated with pregnancy and steroid intake. Patients who were given other forms of medication other than topical non-steroidal anti-inflammatory drug (NSAID) and those who developed recurrences within the study period were also excluded.

We recorded the patients' age, gender, history of smoking, hypertension, diabetes, previous history of CSCR and duration of symptoms. The patients underwent complete ophthalmic examination including: BCVA, slitlamp biomicroscopy (using a 90-diopter lens) on dilated pupil and OCT imaging. BCVA test was done using a trial frame and a projection-type Snellen chart by different

Figure 1 OCT image showing: Macular scan (A) hyperreflective dots (inside circle) (B); PED (star) and RPE bumps (arrow) (C) and retinal 'dragging/dipping' with hyper-reflective flow in the subretinal spacesuggestive of fibrin (star) (D). PED, pigment epithelial detachment; RPE, retinal pigment epithelial.

optometrist but in the same room with standardised low light conditions. All OCT images were obtained through a dilated pupil using spectral domain OCT (Cirrus OCT, Carl Zeiss Meditec, Dublin, California, USA). The OCT scans were evaluated for: (1)CMT, (2) presence and number of HRDs, (3) presence of PEDs, (4) RPE bumps and (5) presence of fibrin in the SRF as shown in figure 1 by the 512×128 macular cube and Cirrus high definition (HD)-OCT enhanced HD 5 line Raster report. Both the scans were done in horizontal (temporal to nasal or vice versa) and vertical (superior to inferior) planes. RPE bump was defined as a slight elevation of the RPE layer without a hyporeflective area inside.¹⁷ We (AP and PJ) counted the HRDs manually within an area of 1500 um radius centred on the fovea using a horizontal raster scan. All the patients were treated with topical ketorolac 0.4% solution (Acular LS; Allergan, Irvine, California, USA) four times daily for 1 month on diagnosis of CSCR.

Patients were reviewed monthly for 6 months. On each visit, they underwent complete slitlamp biomicroscopy examination, BCVA evaluation and SD OCT. The patients were divided into two groups (1 and 2), based on the duration of SRF resolution from the first visit. Group 1 consisted of patients in whom the SRF resolution time was \leq 3 months and group 2 consisted of patients in whom the SRF resolution time was >3 months. We prospectively selected thirty eyes of 30 age-matched and sex-matched normal patients with no ocular and systemic comorbidity as control to calculate normal CMT for comparison. These individuals had come for regular eye evaluation.

The BCVA was converted to logarithm of the minimum angle of resolution (LogMAR) equivalent. We studied the various baseline clinicodemographic factors; the OCT parameters and their association with the SRF resolution time, the final CMT and the final visual outcome.

STATISTICAL ANALYSIS

IBM SPSS Statistics for Macintosh, V.20.0., IBM was used for statistical analysis. We used the independent t-test to evaluate the difference between the groups in terms of age at presentation, duration of symptoms, baseline and final CMT, and baseline and final BCVA. We used the Pearson correlation coefficient (r) to see the relationship between various factors. χ^2 test and Fisher's exact test were used wherever applicable to assess the difference between the two groups by means of the various demographic features (gender, history of smoking, hypertension (HTN) and diabetes mellitus (DM) and the baseline OCT features (presence of HRDs, PED, RPE bumps and fibrin). We used the independent t-test to evaluate the effect of gender difference and the presence or absence of the various OCT features on the duration of SRF resolution, final CMT and final BCVA. The paired t-test was used to calculate the mean difference between the baseline and final BCVA and CMT of the study population. We performed the Mann-Whitney U test to see the difference between the two groups by the actual number of HRDs. Multivariate analysis of variance was done to determine if the duration of SRF resolution, final CMT and final BCVA were affected by the presence or absence of HRDs in the baseline OCT which was followed by a series of one-way ANOVA with a Bonferroni corrected alpha value for each AVOVA test as 0.01667. Multiple regression analysis was performed to predict final BCVA in LogMAR from both duration of SRF resolution and final CMT. Linear regression was performed to aid the visualisation of the relationship of different variables with each other and overlaid on the scatter plots.

PATIENT AND PUBLIC INVOLVEMENT

Patients were not directly involved in the planning of the study. The patients were part of a retrospective audit. Informed consent was obtained from patients whose data were used as control. They did not have to bear any extra financial burden due to their participation in the study.

RESULTS

There were 93 eyes of 93 patients diagnosed with treatment naïve acute idiopathic CSCR presenting within 30 days of onset of symptoms. Table 1 shows the comparison of the clinico-demographic features between the two groups. In group 1, there were 61 eyes of male and 6 eyes of female patients, and in group 2, 19 eyes of male and 7 eyes of female patients (p=0.03, Fisher's exact test). The duration of symptoms in group 1 and 2 was 14.46±5.63 days and 20.58±4.73 days, respectively (t=-4.897, p<0.001, independent t-test). There was no significant difference between the two groups (1 and 2) by means of baseline BCVA in LogMAR $(0.47\pm0.37 \text{ and } 0.44\pm0.24, \text{ respectively},$ t=0.355, p=0.7, independent t-test) and baseline CMT (429.40±96.19 µm and 425.07±90.30 µm, respectively, t=0.198, p=0.8, independent t-test). There was no significant difference between the groups by means of age at presentation (t=-0.140, p=0.8, independent t-test),

Table 1Comparison of the clinicodemographic featuresbetween group 1 and 2

between group 1 and 2								
Features	Group 1	Group 2	P value					
Age (years)	35.76±6.21	35.96±6.22	0.8*					
Male:female	61:6	19:7	0.03†					
Duration of symptoms (days)	14.46±5.63	20.58±4.73	<0.001*					
Baseline BCVA (LogMAR)	0.47±0.37	0.44±0.24	0.7*					
Baseline CMT (µm)	429.40±96.19	425.07±90.30	0.8*					
Smoking (yes:no)	21:46	6:20	0.4‡					
HTN (yes:no)	3:64	4:22	0.09†					
DM (yes:no)	0:67	2:24	0.07†					
Final BCVA (LogMAR)	0.15±0.14	0.39±0.16	<0.001*					
Final CMT (µm)	226.17±12.66	207.26±15.72	<0.001*					

*Independent 't' test.

† Fisher's exact test

 $\pm \chi^2$ test

BCVA, best-corrected visual acuity; CMT, central macular

thickness.

smoking habit (p=0.4, χ^2 test), and presence of hypertension or diabetes (p=0.09, and p=0.07, respectively, Fisher's exact test). Among the 26 patients of group 2, only one had persistence of SRF at 6 months. The patient's SRF had resolved during the examination at the end of 7 months.

The overall average BCVA (LogMAR) improved significantly from 0.46 ± 0.34 at baseline to 0.21 ± 0.18 (t=7.023, p<0.001, paired t-test) at the final visit. The final BCVA (LogMAR) was statistically worse in group 2 compared with group 1, 0.39 ± 0.16 vs 0.15 ± 0.14 (t=7.156, p<0.001, independent t-test).

Likewise the overall average CMT decreased from $428.19\pm94.11 \ \mu m$ at baseline to $220.89\pm15.97 \ \mu m$ (t=20.689, p<0.001, paired t-test) at final visit. The final CMT of the patients of group 1 (226.17±12.66 μm) was statistically thinner than the normal population (241.13±12.95 μm), (t=-5.338, p<0.001, independent t-test); while that of the patients of group 2 (207.26±15.72 μm) was statistically thinner than group 1 (t=-6.029, p<0.001, independent t-test).

Table 2 shows the brief summary of the baseline OCT findings of the patients. Among the OCT parameters at presentation, the two groups were significantly different only in terms of presence of HRDs (p<0.001, χ^2 test). There was no significant difference between the two groups by means of presence of PED, RPE bumps and fibrin (p=0.4, p=0.1, and p=0.2, respectively, χ^2 test). A Mann-Whitney U test showed that there was a significant

OCT features		Distribution am	ong groups (%)		
OCT leatures	Total no of eyes (%)	Group 1	Group2	P value (χ^2 test)	
PED	24 (25.80)	16 (17.20)	8 (8.60)	0.4	
HRDs	33 (35.48)	16 (17.20)	17 (18.27)	<0.001	
RPE bumps	28 (30.10)	17 (18.27)	11 (11.82)	0.1	
Fibrin	21 (22.58)	13 (13.97)	8 (8.6)	0.2	
Table 3 shows that female sex and presence of HRDs and RPE bumps in the baseline OCT were associated with significantly longer duration of SRF resolution (t=2.212, p=0.04, t=3.554, p=0.001, and t=2.602, p=0.01, mean effects of the second					
respectively, independent t-test). However among these factors, presence of HRDs was the only factor associated with significantly poorer final visual outcome (t=3.835,			between the patients with regard to presence or absen of HRDs in their baseline OCT on: (1) duration of S resolution, $F(1,91)=16.309$, p<0.001, partial $\eta 2=0.152$; (
$n = \langle 0 0 \overline{0} 1 \rangle$ indep	endent t-test). We also found t			· ·	
ence of HRDs a	nd RPE bumps in the baseli significantly thinner final CM	ne OCT was (3) f		p=0.004, partial η2=0.065 a 704, p<0.001, partial η2=0.1 aving longer duration of S	

Table 3 shows that female sex and present and RPE bumps in the baseline OCT were with significantly longer duration of SRF (t=2.212, p=0.04, t=3.554, p=0.001, and t=2.6 respectively, independent t-test). However an factors, presence of HRDs was the only facto with significantly poorer final visual outcom p=<0.001, independent t-test). We also found the ence of HRDs and RPE bumps in the baselin associated with significantly thinner final CM p=0.004 and t=-2.581, p=0.01, respectively, in t-test). We observed that the actual number of HRDs in the baseline OCT had a significant correlation with the SRF resolution time (r = +0.336, p=0.001); the final CMT (r=-0.242, p=0.01); and the final BCVA in LogMAR

those without HRDs. Age at presentation did not have any significant correlation with the duration of SRF resolution (r=-0.012, p=0.45); final CMT (r=+0.003, p=0.48) and final BCVA in LogMAR (r=-0.018, p=0.43).

Table 3 Effect of gender and various OCT features on duration of SRF resolution, final visual outcome and final CMT								
Factors	Duration of SRF resolution (months)	P value*	Final LogMAR BCVA	P value*	Final CMT (µm)	P value*		
Gender								
Male (80)	2.46±1.45	0.04	0.20±0.18	0.14	221.96±15.92	0.10		
Female (13)	3.76±2.04		0.28±0.18		214.30±15.22			
HRDs								
Yes (33)	3.48±1.90	0.001	0.31±0.19	<0.001	214.63±17.36	0.004		
No (60)	2.18±1.20		0.16±0.15		224.33±14.15			
RPE bumps								
Yes (28)	3.28±1.78	0.01	0.24±0.20	0.31	214.57±17.90	0.01		
No (65)	2.36±1.45		0.20±0.17		223.61±14.36			
PED								
Yes (24)	2.95±1.68	0.27	0.21±0.20	0.97	221.95±15.81	0.70		
No (69)	2.53±1.57		0.22±0.17		220.52±16.12			
Fibrin								
Yes (21)	3.00±1.84	0.25	0.24±0.17	0.45	217.23±17.54	0.23		
No (72)	2.54±1.52		0.21±0.19		221.95±15.44			

*Independent t-test.

BCVA, best-corrected visual acuity; CMT, central macular thickness; HRDs, hyper-reflective dots; OCT, optical coherence tomography; RPE, Retinal pigment epithelium; SRF, subretinal fluid .

We observed that the duration of symptoms showed significant correlation with the duration of SRF resolution (r=+0.338, p<0.001) and final BCVA in LogMAR (r=+0.210, p=0.02) but failed to show any significant correlation with the final CMT (r=-0.111, p=0.14). The baseline BCVA in LogMAR showed significant correlation with the final BCVA in LogMAR (r=+0.287, p=0.003) and the final CMT (r=-0.19, p=0.03) but failed to show any significant correlation with the SRF resolution time (r=+0.012, p=0.4). However, the baseline CMT had no significant correlation with duration of SRF resolution (r=-0.007, p=0.47) or final CMT (r=-0.07, p=0.23) or final BCVA (r=+0.043, p=0.34). We observed that the SRF resolution time had a strong negative correlation with the final CMT (r=-0.589, p<0.001) and a strong positive correlation with final BCVA in LogMAR (r=+0.599, p<0.001). Likewise the final BCVA in LogMAR had a very strong negative correlation with the final CMT (r=-0.783, p<0.001). We ran a multiple regression analysis to predict the final BCVA in LogMAR from both duration of SRF resolution and final CMT. These variables were statistically significant in prediction of final BCVA, F(2,90)=80.927, p<0.001, $R^2=0.643$. The standardised coefficients beta for duration of SRF resolution and final CMT was 0.212 and -0.659, respectively. Both the variables added statistical significance to the prediction, p<0.05.

For visualisation of these correlations, we overlaid linear regression models of four pairs of data on the scatter plots: duration of symptoms vs duration of SRF resolution; duration of SRF resolution vs final CMT; duration of SRF resolution vs final BCVA in LogMAR; and final CMT vs final BCVA in LogMAR (figure 2).

DISCUSSION

This study supports the hypothesis that prolonged absence of contact between the photoreceptor cells and the RPE cells results in poorer visual outcome in cases of CSCR. The poor vision has been attributed to the damage to the outer retina.^{13 18–20} However, the actual duration required for this irreversible damage to occur is a crude estimation. This is because in majority of the patients, the fellow eye is usually healthy, and thus the duration of symptoms reported by the patient is an unreliable measure. So this designation of chronicity in CSCR is somewhat inconsistent. Some authors define chronicity as persistence of fluid for at least 6 months,²¹ while others as 3 months.^{22–24} We divided the patients in our study into two groups by defining chronicity as persistence of SRF fluid for more than 3 months.

Acute CSCR is believed to be a self-limiting disease. The neurosensory retina usually reattaches within 3–4 months in majority of the cases.²¹ Thus observation is the first-line of treatment in most of the cases.²⁵ Though longer duration of SRF resolution has been associated with worse structural and functional retinal outcome, there has been no consensus regarding the most suitable treatment and the optimal timing for intervention in CSCR patients. We thus studied the patient's baseline




Figure 2 Scatter plots with linear regression (black line) showing relation between: duration of symptoms(days) versus duration of SRF resolution (months) (A); duration of SRF resolution (months) versus final CMT (μ m) (B); duration of SRF resolution (months) versus final BCVA in LogMAR (C) and Final CMT (μ m) versus final BCVA in LogMAR (D). BCVA, best-corrected visual acuity; CMT, central macular thickness; SRF, subretinal fluid.

factors that helped us to predict the clinical course of the disease.

We observed that all the patients with CSCR developed macular thinning after resolution of the SRF. Longer time for SRF resolution was associated with thinner final CMT and worse final BCVA. We also found that eyes with thinner final CMT were associated with worse BCVA at both baseline and at the final visit. Similar correlation between duration of SRF resolution with both final CMT and final visual outcome were noted by Aggio *et al*²⁰ and Wang *et al.*²⁶ Other studies too have reported atrophy of the fovea after resolution of the SRF in cases of CSCR and have correlated the foveal thickness with the final visual acuity.^{27 28}

HRD is one of the various OCT tomographic factors often reported in cases of CSCR.^{16 18 29} These HRDs are believed to be macrophages and disintegrated outer photoreceptor remnants that become deposited in the subretinal or the intraretinal space secondary to failed pumping action of the RPE.^{16 30 31} The overall incidence of HRDs in our study was 35.48%. This is relatively low compared with the incidence rate of 66%, 65%, 57.4% and 50% in the studies by Yalcinbayir *et al*,¹⁶ Maruko *et al*,²⁹ Lai *et al*¹⁸ and Suwal *et al*³², respectively. Lee *et al*¹⁷ stated that increased number of HRDs was associated with recurrences. In their retrospective study, Song *et al*¹⁵ found that HRDs were rarely seen in cases with acute

CSCR and more commonly observed in eyes with early chronic and late chronic CSCR. So the reason behind this low incidence of HRDs in our study might be the exclusion of the cases with recurrences and those having symptoms for more than 30 days before presentation to the hospital.

The presence of intraretinal and/or subretinal HRDs in CSCR has been associated with poor visual prognosis and the need for early intervention.^{16 18} In our study presence of HRDs was associated with significantly longer time for SRF resolution, thinner final CMT and poorer visual outcome. We also observed that the increased number of HRDs in baseline OCT too was associated with significantly longer time for SRF resolution, thinner final CMT and worse final visual outcome. In their retrospective study. Lee *et al*¹⁷ too observed that the number of HRDs observed in baseline SD-OCT correlated positively with both the duration of SRF resolution and the duration of visual recovery. However, they did not observe any correlation between number of HRDs and the final visual outcome. In their study, Suwal *et al*^{β^2} found that eyes with HRDs had persistence of SRF at the end of 3 months and were associated with poor visual outcome.

The overall incidence of RPE bumps in our study was 30.10%. The incidence of RPE bumps has been reported to be 46.4%, 8.1%, 45.2%, and 62.5% in studies by Yalcinbayir *et al*,¹⁶ Lee *et al*,¹⁷ Daruich *et al*,³³ and Suwal *et al*.³² We observed that the presence of RPE bumps in the baseline OCT was associated with significantly longer time for SRF resolution, and thinner final CMT, but it did not have any significant effect on the final visual outcome. No such relations were observed in other studies.¹⁷¹⁸

We observed that eyes with longer duration of symptoms took significantly longer time for SRF resolution and were associated with thinner final CMT and worse final visual outcome. Malik *et al*^{β 4} found that shorter duration of symptoms was associated with better visual outcome, but Furuta *et al*^{β 8} did not find any correlation between duration of symptoms with both BCVA and foveal thickness after the resolution of the SRF.

We observed that worse baseline BCVA was associated with thinner final CMT and poorer final BCVA, but bore no significant correlation to duration of SRF resolution. Malik *et al*^{β 4} also commented that baseline BCVA was a reliable predictor of final visual outcome in CSCR and Lee *et al*¹⁷ stated that worse baseline BCVA was associated with increased time for SRF resolution.

The findings regarding association between age at presentation and gender with disease duration and final visual outcome is different in different studies. We did not find any correlation between disease duration, final CMT, and final visual outcome with age at presentation. In our study female gender was associated with longer disease duration but had no association with final CMT and final visual outcome. Aggio *et al*²⁰ too did not find any significant association between age, gender and final visual acuity. However, there are studies that have reported that women of age ≥ 50 take longer time for

disease resolution³⁵ and is an indication for early intervention.¹⁸ Daruich *et al*³³ found that age \geq 40 years was an independent factor associated with longer disease duration, but Lee *et al*¹⁷ found no relation between duration of SRF resolution and duration of visual acuity recovery with the age of the patient.

In this study, all the patients received topical NSAID for 1 month on diagnosis of the disease as per the hospital's treatment protocol. Few cases have been reported to have developed CSCR following the topical use of latanoprost eye drops, suggesting that prostaglandins too might have a role in the pathogenesis of CSCR.³⁶³⁷ Studies have shown early resorption of the SRF in cases of CSCR with the use of topical NSAIDs.^{38–40} Likewise the use of oral NSAID like aspirin too has been associated with faster visual improvement and reduced rates of CSCR recurrences.⁴¹⁴²

Though the overall average final BCVA of our study population improved significantly (p<0.001), the final visual acuity of the patients in whom the duration of SRF resolution was more than 3 months did not change significantly from the baseline value (t=1.009, p=0.32, paired t-test). All the patients in our study had received topical NSAID for the first month, but still, 26 (27.95%) eyes out of 93 eyes developed chronic CSCR (duration of SRF resolution >3 months) and poor final visual acuity. Based on our assumption that the effects of NSAID was similar on all the eyes, we believe that those cases of treatment naïve acute idiopathic CSCR occurring in females and/or those associated with HRDs and/or RPE bumps in baseline OCT are more likely to develop chronic disease.

The retrospective nature and the lack of control group in the study precluded us from understanding the natural course of the disease. Since the duration of symptoms is significantly less in group 1 patients compared with group 2, it might exaggerate the difference in duration of the entire CSR episode from onset of symptoms to resolution of SRF between the two groups.

In conclusion, in cases of treatment naïve acute idiopathic CSCR, patient's baseline clinicodemographic and OCT features can be used to predict the course of the disease and the visual outcome

Acknowledgements The authors would like to thank Santosh Koirala, PhD, for his assistance in statistics.

Contributors AP and PJ planned the study. AP was involved in data collection and analysis and drafting of the first manuscript. PJ reviewed the literature and edited the manuscript. Both the authors approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Local ethical committee board of the Mechi Eye Hospital.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Anil Parajuli http://orcid.org/0000-0003-0124-152X Purushottam Joshi http://orcid.org/0000-0001-9428-0266

REFERENCES

- 1 Donald J, Gass M. Pathogenesis of disciform detachment of the neuroepithelium: II. idiopathic central serous choroidopathy. *Am J Ophthalmol* 1967;63:1.
- 2 Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008;115:169–73.
- 3 Tsai D-C, Chen S-J, Huang C-C, et al. Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a populationbased study. PLoS One 2013;8:e66858.
- 4 Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. *Ophthalmology* 1996;103:2070–80.
- 5 Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999;128:63–8.
- 6 Spitznas M, Huke J. Number, shape, and topography of leakage points in acute type I central serous retinopathy. *Graefes Arch Clin Exp Ophthalmol* 1987;225:437–40.
- 7 Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. *Int Ophthalmol* 1986;9:37–41.
- 8 Scheider A, Nasemann JE, Lund OE. Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. *Am J Ophthalmol* 1993;115:50–6.
- 9 Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. *Retina* 1994;14:231–42.
- 10 Guyer DR, Yannuzzi LA, Šlakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057–62.
- 11 Baran NV, Gürlü VP, Esgin H. Long-Term macular function in eyes with central serous chorioretinopathy. *Clin Exp Ophthalmol* 2005;33:369–72.
- 12 Folk JC, Thompson HS, Han DP, et al. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol 1984;102:1299–302.
- 13 Nicholson B, Noble J, Forooghian F, *et al*. Central serous chorioretinopathy: update on pathophysiology and treatment. *Surv Ophthalmol* 2013;58:103–26.
- 14 Mrejen S, Sarraf D, Mukkamala SK, et al. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. *Retina* 2013;33:1735–62.
- 15 Song IS, Shin YU, Lee BR. Time-Periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. *Am J Ophthalmol* 2012;154:366–75.
- 16 Yalcinbayir O, Gelisken O, Akova-Budak B, et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. *Retina* 2014;34:705–12.
- 17 Lee H, Lee J, Chung H, et al. Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. *Retina* 2016;36:1372–80.
- 18 Lai W-Y, Tseng C-L, Wu T-T, et al. Correlation between baseline retinal microstructures in spectral-domain optic coherence tomography and need for early intervention in central serous chorioretinopathy. BMJ Open Ophthalmol 2017;2:e000054.
- 19 Loo RH, Scott IÚ, Flynn HW, *et al.* Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. *Retina* 2002;22:19–24.

- 20 Aggio FB, Roisman L, Melo GB, et al. Clinical factors related to visual outcome in central serous chorioretinopathy. *Retina* 2010;30:1128–34.
- 21 Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. *Am J Ophthalmol* 2010;149:361–3.
- 22 Chan W-M, Lai TYY, Lai RYK, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. *Retina* 2008;28:85–93.
- 23 Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010;149:307–15.
- 24 Shin JY, Woo SJ, Yu HG, et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. *Retina* 2011;31:119–26.
- 25 Yannuzzi LA. Type-A behavior and central serous chorioretinopathy. *Retina* 1987;7:111–31.
- 26 Wang MSM, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. *Am J Ophthalmol* 2002;133:787–93.
- 27 Eandi CM, Chung JE, Cardillo-Piccolino F, et al. Optical coherence tomography in unilateral resolved central serous chorioretinopathy. *Retina* 2005;25:417–21.
- 28 Furuta M, Iida T, Kishi S. Foveal thickness can predict visual outcome in patients with persistent central serous chorioretinopathy. *Ophthalmologica* 2009;223:28–31.
- 29 Maruko I, lida T, Ojima A, et al. Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy. *Retina* 2011;31:759–65.
- 30 Matsumoto H, Kishi S, Otani T, et al. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008;145:162–8.
- 31 Kon Y, lida T, Maruko I, et al. The optical coherence tomographyophthalmoscope for examination of central serous chorioretinopathy with precipitates. *Retina* 2008;28:864–9.
- 32 Suwal B, Khadka D, Shrestha A, et al. Baseline predictive factors of visual outcome and persistence of subretinal fluid based on morphologic changes in spectral domain optical coherence tomography in patients with idiopathic central serous chorioretinopathy. *Clin Ophthalmol* 2019;13:2439–44.
- 33 Daruich A, Matet A, Marchionno L, *et al*. Acute central serous chorioretinopathy: factors influencing episode duration. *Retina* 2017;37:1905.
- 34 Malik A, Gupta A, Mithal C, et al. Central serous chorioretinopathy: correlation of structural changes on optical coherence tomography with visual outcomes. *Delta Journal of Ophthalmology* 2017;18:37–43.
- 35 Perkins SL, Kim JE, Pollack JS, *et al.* Clinical characteristics of central serous chorioretinopathy in women. *Ophthalmology* 2002;109:262–6.
- 36 Artunay O, Senel A, Sengul A, et al. Central serous chorioretinopathy associated with topical latanoprost therapy. Ocul Immunol Inflamm 2011;19:453–5.
- 37 Ayhan Tuzcu E, Keskin U, Coskun M, et al. Bilateral serous detachment associated with latanoprost/timolol fixed combination use: a report of one phakic case. Case Rep Ophthalmol Med 2012;2012:1–3.
- 38 Alkin Z, Osmanbasoglu OA, Ozkaya A, et al. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2013;2:96.
- 39 Khan NAet al. Topical Bromfenac in the treatment of central serous chorioretinopathy. Adv Ophthalmol Vis Syst 2017;7:00248.
- 40 Bahadorani S, Maclean K, Wannamaker K, et al. Treatment of central serous chorioretinopathy with topical NSAIDs. *Clin Ophthalmol* 2019;13:1543–8.
- 41 Caccavale A, Imparato M, Romanazzi F, et al. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. *Med Hypotheses* 2009;73:435–7.
- 42 Caccavale A, Romanazzi F, Imparato M, et al. Low-Dose aspirin as treatment for central serous chorioretinopathy. *Clin Ophthalmol* 2010;4:899–903.